Back to today’s briefing

Story perspectives

Viking Therapeutics Secures $150M Deal for Obesity Drug Production

3/12/2025

50 6

Summary

Story summary

Viking Therapeutics is making waves in the obesity treatment arena with a groundbreaking $150 million manufacturing partnership with CordenPharma for its oral drug, VK2735. This deal paves the way for the production of over one billion pills each year. With Phase III trials set for 2025, Viking is poised to tap into a booming market projected to hit $37.1 billion by 2031.

1 of 1

Story summary

Viking Therapeutics is making waves in the obesity treatment arena with a groundbreaking $150 million manufacturing partnership with CordenPharma for its oral drug, VK2735. This deal paves the way for the production of over one billion pills each year. With Phase III trials set for 2025, Viking is poised to tap into a booming market projected to hit $37.1 billion by 2031.